Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Yesterday, Dec. 16, 2014, 105 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $63.36 to $15,595,781.10.
Highlighted Stocks Traded by Insiders:
DigitalGlobe (DGI) - FREE Research Report Zervigon Eddy, who is Director at DigitalGlobe, bought 2,000 shares at $24.84 on Dec. 16, 2014. Following this transaction, the Director owned 5,868 shares meaning that the stake was boosted by 51.71% with the 2,000-share transaction.
Wray Grover N., who is SVP, Chief HR Officer at DigitalGlobe, bought 210 shares at $24.61 on Dec. 16, 2014. Following this transaction, the SVP, Chief HR Officer owned 54,166 shares meaning that the stake was boosted by 0.39% with the 210-share transaction.
The shares most recently traded at $26.10, up $1.49, or 5.71% since the insider transaction. Historical insider transactions for DigitalGlobe go as follows:
- 4-Week # shares bought: 6,043
- 4-Week # shares sold: 3,000
- 12-Week # shares bought: 9,043
- 12-Week # shares sold: 3,000
- 24-Week # shares bought: 9,043
- 24-Week # shares sold: 21,000
The average volume for DigitalGlobe has been 541,000 shares per day over the past 30 days. DigitalGlobe has a market cap of $1.9 billion and is part of the industrial goods sector and aerospace/defense industry. Shares are down 39.56% year-to-date as of the close of trading on Monday.
DigitalGlobe, Inc. provides imagery and imagery information products and services in the United States and internationally. The company has a P/E ratio of 100.0. Currently, there are 6 analysts who rate DigitalGlobe a buy, no analysts rate it a sell, and 1 rates it a hold.
Exclusive Offer: Get the latest Stock Analysis on DGI - FREE TheStreet Quant Ratings rates DigitalGlobe as a
hold. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and weak operating cash flow. Get the full
DigitalGlobe Ratings Report from
TheStreet Quant Ratings now.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
CME Group (CME) - FREE Research Report Harley Jill A, who is Md&Cao at CME Group, sold 400 shares at $87.82 on Dec. 16, 2014. Following this transaction, the Md&Cao owned 11,135 shares meaning that the stake was reduced by 3.47% with the 400-share transaction.
The shares most recently traded at $87.50, down $0.32, or 0.37% since the insider transaction. Historical insider transactions for CME Group go as follows:
- 4-Week # shares sold: 450
- 12-Week # shares bought: 350
- 12-Week # shares sold: 3,270
- 24-Week # shares bought: 350
- 24-Week # shares sold: 7,437
The average volume for CME Group has been 1.6 million shares per day over the past 30 days. CME Group has a market cap of $29.3 billion and is part of the financial sector and financial services industry. Shares are up 12.08% year-to-date as of the close of trading on Monday.
CME Group Inc., through its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. The stock currently has a dividend yield of 2.16%. The company has a P/E ratio of 28.9. Currently, there are 6 analysts who rate CME Group a buy, no analysts rate it a sell, and 5 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on CME - FREE TheStreet Quant Ratings rates CME Group as a
buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, growth in earnings per share, increase in net income, revenue growth and reasonable valuation levels. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full
CME Group Ratings Report from
TheStreet Quant Ratings now.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Derma (DSCI) - FREE Research Report Conjeevaram Srini, who is Director at Derma, sold 12,500 shares at $8.49 on Dec. 16, 2014. Following this transaction, the Director owned 48,250 shares meaning that the stake was reduced by 20.58% with the 12,500-share transaction.
The shares most recently traded at $8.19, down $0.30, or 3.64% since the insider transaction. Historical insider transactions for Derma go as follows:
- 4-Week # shares bought: 3,750
- 4-Week # shares sold: 7,850
- 12-Week # shares bought: 3,750
- 12-Week # shares sold: 17,973
- 24-Week # shares bought: 3,750
- 24-Week # shares sold: 17,973
The average volume for Derma has been 83,900 shares per day over the past 30 days. Derma has a market cap of $217.1 million and is part of the health care sector and health services industry. Shares are down 24.12% year-to-date as of the close of trading on Monday.
Derma Sciences, Inc. operates as a tissue regeneration company in the wound care market. It operates in three segments: Advanced Wound Care, Traditional Wound Care, and Pharmaceutical Wound Care. Currently, there are 3 analysts who rate Derma a buy, no analysts rate it a sell, and none rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on DSCI - FREE TheStreet Quant Ratings rates Derma as a
sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income and generally disappointing historical performance in the stock itself. Get the full
Derma Ratings Report from
TheStreet Quant Ratings now.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
